TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC ...

Read Also: ‘Pharma Bro’ Martin Shkreli Tells Investors To ‘Short SAVA,’ Stock Falls Over 80% After Phase 3 Update According to data from Benzinga Pro, RNAZ has a 52-week high of $18.48 and ...

TransCode Therapeutics (NASDAQ:RNAZ) stock is sliding lower on Monday following its announcement of an upcoming annual shareholder meeting. TransCode Therapeutics has informed investors in RNAZ ...

Shares of RNAZ stock opened at $3.58 on Monday. TransCode Therapeutics has a 52 week low of $3.21 and a 52 week high of $264.00. The stock has a fifty day moving average of $380.38 and a 200 day ...

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split ...

Sheets Smith Wealth Management raised its holdings in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 149.0% in the third quarter, according to its most recent Form 13F ...

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The company announced a 1-for-33 reverse stock split. TransCode Therapeutics Inc RNAZ shares are trading lower by 16% to 29 cents during Monday’s session after the company announced a 1-for-33 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...